Abstract
Heparanase is an endoglycosidase that degrades heparan sulfate side chains of heparan sulfate-proteoglycans. It liberates heparan sulfate-bound growth factors and thereby promotes blood vessel sprouting and angiogenesis. The subterranean blind mole rat, Spalax, is a wild mammal that lives most of its life in underground tunnels where it experiences sharp fluctuations in oxygen and carbon dioxide levels. We described two splice variants of heparanase from Spalax, Splice 7 and splice 36, both devoid of heparanase enzymatic activity. Splice 7 increases tumor growth, while splice 36 functions as a dominant negative to wild-type heparanase and decreases tumor growth and metastasis. Here, we describe two novel splice variants of Spalax heparanase, splice 67 and splice 612. These splice variants result in production of a shorter heparanase proteins that are similar to the wild-type native heparanase in their N-terminal but have unique C-terminals. Both splice 67 and 612 lack heparan sulfate degradation activity.
Original language | English |
---|---|
Pages (from-to) | 885-889 |
Number of pages | 5 |
Journal | Anti-Cancer Drugs |
Volume | 31 |
Issue number | 9 |
DOIs | |
State | Published - 1 Oct 2020 |
Bibliographical note
Publisher Copyright:© 2020 Lippincott Williams and Wilkins. All rights reserved.
Keywords
- Spalax
- alternative splicing
- angiogenesis
- cancer
- heparanase
- hypoxia
ASJC Scopus subject areas
- Oncology
- Pharmacology
- Pharmacology (medical)
- Cancer Research